Progress in Understanding the Immunopathogenesis of Psoriasis
Authors:
- R.K.H. MakRMR.K.H. Mak
- C. HundhausenCHC. Hundhausen
- F.O. NestleFNF.O. Nestle
- 1 December 2009
- journal article
- review article
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 100, 2-13
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- PsoriasisNew England Journal of Medicine, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility geneHuman Molecular Genetics, 2008
- The Risk of Mortality in Patients With PsoriasisArchives of Dermatology, 2007
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesisJournal of Experimental Medicine, 2006
- The importance of disease associations and concomitant therapy for the long-term management of psoriasis patientsArchives of Dermatological Research, 2006
- Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasisArchives of Dermatological Research, 2006
- Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 GeneThe American Journal of Human Genetics, 2006
- Disease concomitance in psoriasisJournal of the American Academy of Dermatology, 1995